Buprenorphine Implants and Opioid Dependence

JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 01/2011; 305(3):253-4; author reply 254. DOI: 10.1001/jama.2010.1989
Source: PubMed
1 Follower
0 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate safety and efficacy of buprenorphine implants (BI) versus placebo implants (PI) for the treatment of opioid dependence. A secondary aim compared BI to open-label sublingual buprenorphine/naloxone tablets (BNX). Randomized, double-blind, placebo-controlled trial. Subjects received either 4 buprenorphine implants (80 mg/implant) (n=114), 4 placebo implants (n=54), or open-label BNX (12-16mg/d) (n=119). 20 addiction treatment centers. Adult outpatients (ages 18 to 65) with DSM-IV-TR opioid dependence. The primary efficacy endpoint was the percent of urine samples negative for opioids collected from weeks 1 to 24, examined as a cumulative distribution function (CDF). The BI CDF was significantly different from placebo (P<.0001). Mean (95% CI) proportions of urines negative for opioids were: BI: 31.2% (25.3, 37.1) and PI: 13.4% (8.3, 18.6). BI subjects had a higher study completion rate relative to placebo (64% vs. 26%, P<.0001), lower clinician-rated (P<.0001) and patient-rated (P<.0001) withdrawal, lower patient-ratings of craving (P<.0001), and better subjects' (P=.031) and clinicians' (P=.022) global ratings of improvement. BI also resulted in significantly lower cocaine use (P=.0016). Minor implant-site reactions were comparable in the buprenorphine (27.2% [31/114]) and placebo groups (25.9% [14/54]). BI were non-inferior to BNX on percent urines negative for opioids [mean (95% CI): 33.5 (27.3, 39.6); CI for the difference of proportions, (-10.7, 6.2)]. Compared with placebo, buprenorphine implants result in significantly less frequent opioid use, and are non-inferior to sublingual buprenorphine/naloxone tablets.
    Full-text · Article · Aug 2013 · Addiction
  • Source

    Full-text · Article · Dec 2013 · Addiction